Michael Hallek, Director of Clinic I for Internal Medicine and Associated Principle Investigator at the University Hospital Cologne, shared on LinkedIn about a paper he co-authored with colleagues published in NEJM:
“Just out in the New England Journal of Medicine: the results of the CLL17 study of a consortium of international study groups and partners led by the German CLL Study Group, GCLLSG.
The study shows that fixed duration combination therapies using venetoclax plus ibrutinib or venetoclax plus obinutuzumab are non-inferior to a continuous monotherapy with ibrutinib in the first line therapy of chronic lymphocytic leukemia, CLL.
We are grateful to our patients who accepted to participate in this study, to the international study teams and congratulate the first author Othman Al-Sawaf, whose relentless effort has made this success possible.
The paper will be presented at the plenary Session of the American Society of Hematology in a few seconds.”
Title: Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
Authors: Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch, Emadoldin Feyzi, Paolo Ghia, Michael Gregor, Arnon P. Kater, Vesa Lindström, Mattias Mattsson, Carsten U. Niemann, Philipp B. Staber, Tamar Tadmor, Patrick Thornton, Clemens-Martin Wendtner, Ann Janssens, Thomas Noesslinger, Jan-Paul Bohn, Caspar da Cunha-Bang, Christian B. Poulsen, Juha Ranti, Thomas Illmer, Bjoern Schoettker, Sebastian Böttcher, Tobias Gaska, Elisabeth Vandenberghe, Ruth Clifford, Ohad Benjamini, Anna Maria Frustaci, Lydia Scarfò, Paolo Sportoletti, John Schreurs, Mark-David Levin, Hanneke van der Straaten, Marjolein van der Klift, Hoa Tran, Javier de la Serna, Javier Loscertales, Oscar Lindblad, Anna Bergendahl Sandstedt, Jeroen Goede, Michael Baumann, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Karl-Anton Kreuzer, Christof Schneider, Eugen Tausch, Stephan Stilgenbauer, Sandra Robrecht, Barbara Eichhorst, Michael Hallek
You can read the full article in New England Journal of Medicine.
More posts featuring Michael Hallek.